Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD3TWM2OD1yLkC2NUDPxE1? Mk[2V2FPT0WU
ALL-PO NVTpd2NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTi[2lPUUN3ME2wMlA3OzV3IN88US=> MVTTRW5ITVJ?
697 NEHFS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LGOGlEPTB;MD6wPVk4PiEQvF2= MVzTRW5ITVJ?
NCI-H748 M1rYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMUCzN|Qh|ryP MnXQV2FPT0WU
NKM-1 NWnKb4x5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jWWmlEPTB;MD6xNFkyOiEQvF2= M1XUUnNCVkeHUh?=
ES1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPZTWM2OD1yLkGxNlU2KM7:TR?= NV:yOVZ7W0GQR1XS
NCI-H1963 NHvafXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3QUWVKSzVyPUCuNVE2PzlizszN NYjVUVBEW0GQR1XS
NCI-H1417 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rQdmlEPTB;MD6xNlk4PCEQvF2= MXnTRW5ITVJ?
NEC8 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml74TWM2OD1yLkGzOVI4KM7:TR?= MV3TRW5ITVJ?
CRO-AP2 NEXDS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELkdXFKSzVyPUCuNVY5QDlizszN MUHTRW5ITVJ?
A3-KAW M3\l[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnrXHl5UUN3ME2wMlE4PjJ5IN88US=> NUHRdJFoW0GQR1XS
SF539 Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DyTGlEPTB;MD6xPVU6OyEQvF2= NHrqfGVUSU6JRWK=
NOS-1 M3rrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTiTWM2OD1yLkG5OlE6KM7:TR?= NF3lcY9USU6JRWK=
NTERA-S-cl-D1 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[4PGlEPTB;MD6yNFEyOyEQvF2= MV\TRW5ITVJ?
COR-L88 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMkK5OVkh|ryP MVPTRW5ITVJ?
EM-2 Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMkSwO|kh|ryP MY\TRW5ITVJ?
KARPAS-45 NH3URlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi5O2I2UUN3ME2wMlI4QDN|IN88US=> MkG2V2FPT0WU
DSH1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DyOmlEPTB;MD6yPFcxQCEQvF2= Ml6xV2FPT0WU
HT-144 M2jPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO0TmtsUUN3ME2wMlMxOjV4IN88US=> MWrTRW5ITVJ?
ATN-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPhfWZKSzVyPUCuN|A2PzZizszN MYHTRW5ITVJ?
HEL NVruOYI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnmdlBKSzVyPUCuN|E{PDhizszN MXvTRW5ITVJ?
NB12 NFPwUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\NSlJKSzVyPUCuN|E4PTZizszN Mn33V2FPT0WU
LU-139 MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe4SZdNUUN3ME2wMlM{PTFizszN M{DJcXNCVkeHUh?=
J-RT3-T3-5 M4XY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLaSIQ{UUN3ME2wMlM{PzF4IN88US=> M{fIVHNCVkeHUh?=
MOLT-13 NUXYfIl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX31SVVKUUN3ME2wMlM{QDFizszN MkjEV2FPT0WU
SR M4X6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDwcnhKSzVyPUCuN|QzPjFizszN M4r0S3NCVkeHUh?=
CMK MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwM{W3Nlch|ryP MmfOV2FPT0WU
ES8 NH\oVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\XTWM2OD1yLkO2NFIzKM7:TR?= NWTxXVRCW0GQR1XS
LB647-SCLC MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rnVWlEPTB;MD6zOlc{KM7:TR?= NH;FUIZUSU6JRWK=
TE-8 NWP6b5VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jz[WlEPTB;MD6zOlk{PSEQvF2= NHK3dmNUSU6JRWK=
BV-173 NWHTNlRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwM{exNlEh|ryP M3TYUnNCVkeHUh?=
DEL NFjpTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwM{e0PFch|ryP NInyd3ZUSU6JRWK=
ARH-77 NFTsNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[xTGlEPTB;MD6zPFE6OyEQvF2= NFTtTJlUSU6JRWK=
NCCIT NVfLe|UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwM{i2OFkh|ryP NIHOZ2VUSU6JRWK=
RPMI-8402 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwM{i3NFEh|ryP NXniTYFFW0GQR1XS
MONO-MAC-6 NIrVToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D2fWlEPTB;MD6zPFc4PiEQvF2= NXuxNHAyW0GQR1XS
SK-MM-2 NVnmXXRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\zS2lEPTB;MD6zPVg3QCEQvF2= MUPTRW5ITVJ?
CHP-126 NEnwS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwNECyN|Eh|ryP MXLTRW5ITVJ?
A101D M1qyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTlcoRKSzVyPUCuOFA{KM7:TR?= MV\TRW5ITVJ?
SCH MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwNECzOFIh|ryP MUnTRW5ITVJ?
NMC-G1 NUm3N2NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwNECzOlch|ryP NES2TFFUSU6JRWK=
NCI-H209 NYPNZYNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ftNWlEPTB;MD60NFYyOyEQvF2= M2fON3NCVkeHUh?=
MOLT-16 MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;YfmlEPTB;MD60NVAyPyEQvF2= M3:5bnNCVkeHUh?=
RPMI-6666 NY\KWmt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwNEGxNkDPxE1? NX65XGxiW0GQR1XS
OPM-2 NInsOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkntTWM2OD1yLkSxOVE{KM7:TR?= NXjBd4ltW0GQR1XS
MRK-nu-1 NFL1SWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\tfmlEPTB;MD60N|E2OyEQvF2= MWXTRW5ITVJ?
BC-1 NITIc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwNEO0NFMh|ryP Mn2xV2FPT0WU
MHH-NB-11 NWDHc4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwNEO0OVMh|ryP M{T1SnNCVkeHUh?=
Ramos-2G6-4C10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qzemlEPTB;MD60N|g6PyEQvF2= MoPxV2FPT0WU
LS-513 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HNdGlEPTB;MD60OFUxOSEQvF2= NX3MS4dnW0GQR1XS
K5 NHP5OI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C2cmlEPTB;MD60O|AzPSEQvF2= Mmi5V2FPT0WU
HOP-62 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHVTWM2OD1yLkS4N|U5KM7:TR?= NXfG[o1NW0GQR1XS
NCI-H187 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;4TWM2OD1yLkS5NlI4KM7:TR?= NI\QSI9USU6JRWK=
BE-13 NIrCOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTtO3NqUUN3ME2wMlQ6PjZzIN88US=> NHPtdJBUSU6JRWK=
HC-1 NHjB[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrOT5ZKSzVyPUCuOVA1PzNizszN MnfiV2FPT0WU
ACN Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjEflNKSzVyPUCuOVExOjhizszN M1TEU3NCVkeHUh?=
HCC1599 NVj6[Zp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHCTWM2OD1yLkWxOVch|ryP MkLvV2FPT0WU
MV-4-11 MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T6dmlEPTB;MD61N|A1OSEQvF2= NWHxXFJjW0GQR1XS
LC-2-ad M4D0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\xTWM2OD1yLkWzOlY{KM7:TR?= M{eweHNCVkeHUh?=
HL-60 NUHmWmpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwNUSyOlEh|ryP MljFV2FPT0WU
NB17 NUXjUJlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTVTWM2OD1yLkW0N|gh|ryP M{D6NHNCVkeHUh?=
TE-1 M4XwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T6dGlEPTB;MD61OVMxPiEQvF2= MofNV2FPT0WU
NCI-H524 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TJVWlEPTB;MD61OVQxOSEQvF2= MoS3V2FPT0WU
MZ7-mel M3TzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwNU[xNFUh|ryP Ml;RV2FPT0WU
L-363 M3XSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP4R3JtUUN3ME2wMlU3PjV5IN88US=> M3jNSnNCVkeHUh?=
BL-41 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwNU[4PFkh|ryP Mkf0V2FPT0WU
LU-134-A NXe5UmNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjGcphNUUN3ME2wMlU4ODd|IN88US=> MmDhV2FPT0WU
SIG-M5 NH[5[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK1[FA3UUN3ME2wMlU4QDR6IN88US=> NE\LPWpUSU6JRWK=
ONS-76 NGO1WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFSzT5BKSzVyPUCuOVgzPDJizszN M3G5W3NCVkeHUh?=
KARPAS-299 NH\TO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TsWmlEPTB;MD61PFUxPCEQvF2= MkXiV2FPT0WU
DU-4475 NGPlV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSzOnc{UUN3ME2wMlU5PzB|IN88US=> M1fQeXNCVkeHUh?=
NB69 NXzVXGU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jkTWlEPTB;MD61PVgzPSEQvF2= M2nte3NCVkeHUh?=
MHH-PREB-1 NYPMb4l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTkTWM2OD1yLk[wO|E6KM7:TR?= M4mycHNCVkeHUh?=
LU-165 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfDdndKSzVyPUCuOlE5OTJizszN MnvYV2FPT0WU
LOUCY M33DRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwNkOzOlQh|ryP M4XDbnNCVkeHUh?=
NCI-H526 NIjDXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwNkO1OFEh|ryP NGLhRppUSU6JRWK=
KE-37 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLkTWM2OD1yLk[0Nlc3KM7:TR?= NIfuU4dUSU6JRWK=
NALM-6 NV3tdpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlraTWM2OD1yLk[0PFYh|ryP M2C4OnNCVkeHUh?=
CW-2 NI\GT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXqTWM2OD1yLk[1O|k1KM7:TR?= M1HoWnNCVkeHUh?=
SU-DHL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof6TWM2OD1yLk[1PVQ4KM7:TR?= MWrTRW5ITVJ?
NB13 M4fGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwNk[4NVch|ryP NXHZcIFlW0GQR1XS
QIMR-WIL NX3xN3BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DzNWlEPTB;MD62PFM1OyEQvF2= MYDTRW5ITVJ?
ECC12 NV3YRmRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon1TWM2OD1yLkewNFg3KM7:TR?= MXTTRW5ITVJ?
KALS-1 NWfENXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHroeoVKSzVyPUCuO|A1QTJizszN MUPTRW5ITVJ?
COR-L279 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf1TWM2OD1yLkewPVk3KM7:TR?= MULTRW5ITVJ?
NB14 NFLleJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfQN4tKSzVyPUCuO|I3OTdizszN M{PvR3NCVkeHUh?=
CCRF-CEM M2DOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwN{S2OlEh|ryP MVTTRW5ITVJ?
SW954 NHPxOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwN{W5PVkh|ryP M3G1cHNCVkeHUh?=
IST-SL1 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjhTWM2OD1yLke3N|Q5KM7:TR?= NH7ocWNUSU6JRWK=
LAMA-84 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf5cpZKSzVyPUCuO|c2PjdizszN NWHJVHdXW0GQR1XS
Daudi NVjYPFhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fGfGlEPTB;MD63O|Y5OSEQvF2= MVrTRW5ITVJ?
BC-3 NUflNGxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\E[XBvUUN3ME2wMlc5OzB6IN88US=> MXzTRW5ITVJ?
HCC2998 NH3uRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvJTWM2OD1yLke4N|Yh|ryP NXzaO4R1W0GQR1XS
NCI-H69 M3njR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXjW2FOUUN3ME2wMlgxOTR5IN88US=> NEDPT|FUSU6JRWK=
CPC-N NVSyPJgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILDUoZKSzVyPUCuPFA2OjRizszN NWHYboV[W0GQR1XS
NOMO-1 NYric415T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7BW|JKSzVyPUCuPFExQDRizszN M2f3THNCVkeHUh?=
CESS MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT1b3JyUUN3ME2wMlgyOTl5IN88US=> M2LUPXNCVkeHUh?=
LC4-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfDTWM2OD1yLki0NFA4KM7:TR?= M{ewXHNCVkeHUh?=
BL-70 NVLtcFlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7wXpN{UUN3ME2wMlg2PzB{IN88US=> Ml25V2FPT0WU
ES4 NYriPVNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPEPVJnUUN3ME2wMlg2QDZ6IN88US=> MYnTRW5ITVJ?
HCE-T MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;0TWM2OD1yLki3NVcyKM7:TR?= MWTTRW5ITVJ?
JAR NYHTT3dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwOEe4Nlch|ryP NHzxR3ZUSU6JRWK=
ST486 NVO3O4diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nGc2lEPTB;MD64O|kyPyEQvF2= Mn\PV2FPT0WU
KS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjIbYhKSzVyPUCuPFgxQTZizszN M{\ubXNCVkeHUh?=
GDM-1 Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3LSYVKSzVyPUCuPFg3QDdizszN NHm5SVVUSU6JRWK=
EHEB M2HXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nqUmlEPTB;MD65NlU5PSEQvF2= M{fs[XNCVkeHUh?=
LB2518-MEL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrnTXRKSzVyPUCuPVMzQDRizszN M1;VfXNCVkeHUh?=
GOTO NWXBcnI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHWTWM2OD1yLkm1NFc3KM7:TR?= NXPPRopqW0GQR1XS
LXF-289 NVrIPYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\acWpKSzVyPUCuPVU6ODFizszN NXGx[WI6W0GQR1XS
ES6 NIP3WZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PiWWlEPTB;MD65OlQ{PyEQvF2= NWHsVHNOW0GQR1XS
OS-RC-2 NIPxfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDqe5F{UUN3ME2wMlk3QDNizszN NVTObVdmW0GQR1XS
DMS-153 M{\JV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHXfpdHUUN3ME2wMlk4PDZ7IN88US=> Ml\jV2FPT0WU
SK-PN-DW NYTQZ4NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK5dHdQUUN3ME2wMlk4QDNzIN88US=> NWrvRmtHW0GQR1XS
HH NX7iWXVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ZW|JKSzVyPUCuPVg6PTlizszN NGrwZWRUSU6JRWK=
SH-4 NW\lU5JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:weoVKSzVyPUGuNFI1OSEQvF2= MoPhV2FPT0WU
MOLT-4 NFnrUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwMEO0OVQh|ryP M3X2SHNCVkeHUh?=
TGW MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK4TVV{UUN3ME2xMlA4Pjd3IN88US=> MWLTRW5ITVJ?
L-540 NYXtR2VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rYPWlEPTB;MT6xNFYxPCEQvF2= NFf3fmRUSU6JRWK=
PF-382 NW\BN3NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7YTWM2OD1zLkGxOVE{KM7:TR?= MXzTRW5ITVJ?
LC-1F MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwMUKwNFch|ryP NGfiSJFUSU6JRWK=
OVCAR-4 M{LBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwMUOxOlUh|ryP M136fXNCVkeHUh?=
A4-Fuk Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK2WGh6UUN3ME2xMlE2OzZ2IN88US=> NF3ZTFJUSU6JRWK=
HCC2218 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHteo0{UUN3ME2xMlE3PjRzIN88US=> MnfyV2FPT0WU
HAL-01 NGPhXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwMU[5OFMh|ryP NXfWRoQ6W0GQR1XS
IST-MEL1 M4PzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvBTWM2OD1zLkG3OlU6KM7:TR?= NHHHbIVUSU6JRWK=
NCI-H719 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PmOWlEPTB;MT6xO|g6QCEQvF2= NHjMR3RUSU6JRWK=
EVSA-T M{XCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnJSlZKSzVyPUGuNVgyOTRizszN Mm\lV2FPT0WU
SK-NEP-1 NUXHTWdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjFS5NKSzVyPUGuNlAzPjZizszN NHPlTJBUSU6JRWK=
OCUB-M MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTjTWM2OD1zLkKxOFg6KM7:TR?= NED0WlVUSU6JRWK=
MEG-01 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLkTWM2OD1zLkKyNVE5KM7:TR?= M3jvXHNCVkeHUh?=
no-10 MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnzZ4NZUUN3ME2xMlI{OTF{IN88US=> NWjNXoZkW0GQR1XS
MHH-CALL-2 NVfyW29ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXyTWM2OD1zLkK0O|IyKM7:TR?= MWLTRW5ITVJ?
SK-N-DZ NHnxSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrEcpBKSzVyPUGuNlQ4PzZizszN MVTTRW5ITVJ?
SCLC-21H NYrsS|F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwMk[0O|gh|ryP MWLTRW5ITVJ?
CTV-1 M3Xwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnCeoFKSzVyPUGuNlc1OjVizszN MUHTRW5ITVJ?
NB1 MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;STWM2OD1zLkK3O|MzKM7:TR?= NIjDXmNUSU6JRWK=
NCI-H64 M2jvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OyUWlEPTB;MT6yPFQ3OiEQvF2= MVTTRW5ITVJ?
MDA-MB-134-VI NGD3R2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmxdWE5UUN3ME2xMlI5PTd5IN88US=> NH6xWGVUSU6JRWK=
LB2241-RCC Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULZS2dIUUN3ME2xMlI5PjZ|IN88US=> NG\YTWdUSU6JRWK=
8-MG-BA Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGwcoRvUUN3ME2xMlI5QDZ4IN88US=> M3fvPXNCVkeHUh?=
LP-1 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M372S2lEPTB;MT6yPVk1PyEQvF2= MkXiV2FPT0WU
LS-411N M1HOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwM{C5PVgh|ryP M1jNWHNCVkeHUh?=
CAL-148 NFPiR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\rZmlEPTB;MT6zNlU1OiEQvF2= NVf4O5lXW0GQR1XS
NCI-H2171 M124d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHwTWM2OD1zLkO0OVAzKM7:TR?= NXXifHRyW0GQR1XS
JiyoyeP-2003 MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXEZVNKSzVyPUGuN|U{QSEQvF2= M3PFbHNCVkeHUh?=
NCI-H2107 NYK1R2VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwM{W4PFMh|ryP NHHVfmRUSU6JRWK=
BB30-HNC NVrYOVVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPvTWM2OD1zLkO4PVc5KM7:TR?= MVHTRW5ITVJ?
K-562 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGzNlRKSzVyPUGuN|kzOTlizszN MmHVV2FPT0WU
PSN1 M4\0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nSTmlEPTB;MT60NlI5PyEQvF2= NHr3[WpUSU6JRWK=
HCC2157 M{D6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHXTWM2OD1zLkSyOlkyKM7:TR?= MVzTRW5ITVJ?
SBC-1 M3TLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\HOZRqUUN3ME2xMlQzPzRzIN88US=> Ml:2V2FPT0WU
MC116 NH7zeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjxe5JKSzVyPUGuOFM3OTVizszN NVmxS5lyW0GQR1XS
KARPAS-422 NV7KSXVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkewTWM2OD1zLkS1N|U5KM7:TR?= NILBenBUSU6JRWK=
LB996-RCC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP0Xm1KSzVyPUGuOFcyODNizszN MVjTRW5ITVJ?
MSTO-211H NUHPTFBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXrXW1RUUN3ME2xMlQ4QTh5IN88US=> M3TCZXNCVkeHUh?=
BT-474 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLVTWM2OD1zLkWxO|Y1KM7:TR?= NFLDNmNUSU6JRWK=
A388 NXL3PHMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljqTWM2OD1zLkWxPVQ2KM7:TR?= MWnTRW5ITVJ?
SJSA-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTpflAyUUN3ME2xMlUzOjZizszN NGLoVZVUSU6JRWK=
COLO-829 NXHaTIZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwNUO1OlQh|ryP NInnVFlUSU6JRWK=
KM-H2 MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rjVWlEPTB;MT61OlY4KM7:TR?= NW\WcFlyW0GQR1XS
GR-ST M{G3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC1bpNQUUN3ME2xMlU3QDJizszN MkTiV2FPT0WU
RPMI-8866 M2DFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn6TWM2OD1zLk[wNVQ1KM7:TR?= NWPmfIk6W0GQR1XS
KG-1 M335WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFwNkG5NFEh|ryP MWjTRW5ITVJ?
NCI-H82 NVTtbGl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\PTWM2OD1zLk[zOFA3KM7:TR?= MlrXV2FPT0WU
LB1047-RCC NXqyeotoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwNkO0OVkh|ryP MlzDV2FPT0WU
KM12 NHH1UoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml74TWM2OD1zLk[0O{DPxE1? NH;4SnpUSU6JRWK=
NB5 M2PYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwNkW2O|ch|ryP M2DPdnNCVkeHUh?=
HDLM-2 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT2WVJKSzVyPUGuOlgzQDFizszN NVjvT2RWW0GQR1XS
KU812 MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfCbVE5UUN3ME2xMlY6PjB3IN88US=> NGTKdohUSU6JRWK=
DB MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXtVlY6UUN3ME2xMlcxOzV|IN88US=> MmnzV2FPT0WU
HD-MY-Z NWfpe|VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PhWmlEPTB;MT63OVI{PCEQvF2= MXPTRW5ITVJ?
KURAMOCHI NIW3bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwN{eyNFch|ryP M{XrOnNCVkeHUh?=
ETK-1 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELxdnlKSzVyPUGuO|g5PzlizszN NVvmboI1W0GQR1XS
SK-UT-1 NY\YSJhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fmXmlEPTB;MT63PVM5QCEQvF2= MoPOV2FPT0WU
HUTU-80 M4DaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETMVmFKSzVyPUGuO|k2ODhizszN M2DzXnNCVkeHUh?=
ES7 M1;BdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTkWXpKSzVyPUGuPFA{ODJizszN NYjNXlVuW0GQR1XS
SW872 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDIcpNUUUN3ME2xMlgyOzl3IN88US=> MljwV2FPT0WU
TK10 M2PldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwOEOxNFgh|ryP M3Thc3NCVkeHUh?=
LB831-BLC M3z2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnFTWM2OD1zLkizOVY{KM7:TR?= NF7JOlJUSU6JRWK=
TE-9 NHjQN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvWTWM2OD1zLki0OFIzKM7:TR?= M33FTXNCVkeHUh?=
MLMA MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS0Z5VMUUN3ME2xMlg5OjN2IN88US=> NVLhfXA3W0GQR1XS
D-542MG M3v4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPyZZR4UUN3ME2xMlg6Ozd|IN88US=> Ml\GV2FPT0WU
EW-16 M{DaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwOUK3NkDPxE1? M2nxPHNCVkeHUh?=
LOXIMVI NUj3fYZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjJTWM2OD1zLkmzNlgh|ryP MXfTRW5ITVJ?
GB-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP5TWM2OD1zLkmzPFY3KM7:TR?= NWXGS5lNW0GQR1XS
IST-SL2 NFXjcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XhS2lEPTB;Mj6wNFI3OiEQvF2= NVXS[ZFjW0GQR1XS
LAN-6 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXaSndFUUN3ME2yMlAyQTZ4IN88US=> MmrtV2FPT0WU
NCI-H510A Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr6ZWlpUUN3ME2yMlA1PTB{IN88US=> Mne4V2FPT0WU
NCI-H1092 NV;acolnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHJTWM2OD1{LkC1NVI1KM7:TR?= NGC1cm9USU6JRWK=
HT M2rGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJwMUC0OVQh|ryP NHW5VWJUSU6JRWK=
RL95-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwMUG0PFIh|ryP NGP1RpdUSU6JRWK=
NCI-H1355 NV:1RVhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrQdVJNUUN3ME2yMlEyPzl{IN88US=> NFjqNIxUSU6JRWK=
NCI-H720 NVHnR|lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuxTWM2OD1{LkG2PFc{KM7:TR?= M4DBXnNCVkeHUh?=
NCI-H1522 NFrHUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfsdIFKSzVyPUKuNlE4OjNizszN MoHSV2FPT0WU
LB373-MEL-D MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojRTWM2OD1{LkK2PVAzKM7:TR?= M3OwfXNCVkeHUh?=
DG-75 NFK5bVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3zTWM2OD1{LkK3NVQ5KM7:TR?= MX\TRW5ITVJ?
ML-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfuO44zUUN3ME2yMlMzQDV3IN88US=> NWWxepdUW0GQR1XS
SF126 M1K4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\EWmlEPTB;Mj6zN|A6PCEQvF2= MkHmV2FPT0WU
MPP-89 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXiNJdKSzVyPUKuN|MyPDVizszN NVXvXHdnW0GQR1XS
NCI-H345 NVnGVoI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX5fG1KSzVyPUKuN|MzPzdizszN NEfDSHhUSU6JRWK=
LS-123 M3O2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULYbo1mUUN3ME2yMlM1QTN4IN88US=> NVTublRuW0GQR1XS
NB10 NYnoS49pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm2TWM2OD1{LkSxNFkzKM7:TR?= NUfENGh2W0GQR1XS
CGTH-W-1 NUjmXZU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M360WGlEPTB;Mj60NlI3PyEQvF2= MlPGV2FPT0WU
CP66-MEL NUfvT441T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvFTWM2OD1{LkS3O|ch|ryP MULTRW5ITVJ?
L-428 M2m1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJwNEi1NlEh|ryP MlPDV2FPT0WU
DMS-79 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwNUSxNFMh|ryP NVyze5k4W0GQR1XS
NCI-H1882 NYS3U|RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4GwO2lEPTB;Mj62O|U3OiEQvF2= MkX2V2FPT0WU
KGN NVvMTlV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWz[HpjUUN3ME2yMlc3QDd4IN88US=> NH76dmtUSU6JRWK=
EW-1 M4LIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXCTWM2OD1{Lke3NFg{KM7:TR?= NUDINY8xW0GQR1XS
U-266 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X0RWlEPTB;Mj64OFgzOyEQvF2= MXPTRW5ITVJ?
COLO-320-HSR MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwOEW2OFEh|ryP NWXaOWZ7W0GQR1XS
KMOE-2 NX;aU|dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnnUIFrUUN3ME2yMlg4PzFzIN88US=> NF\ZRXJUSU6JRWK=
BB49-HNC NInIeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPUR5FKSzVyPUKuPVI1QCEQvF2= M{T1WHNCVkeHUh?=
GI-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJwOUK5OVch|ryP M2np[XNCVkeHUh?=
NCI-H1304 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zYNWlEPTB;Mz6wNFUyOSEQvF2= NVHGPXBlW0GQR1XS
NCI-H2227 NULuc2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfGTWM2OD1|LkCyNFc6KM7:TR?= MXjTRW5ITVJ?
U-87-MG M{\FPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXZUJQ5UUN3ME2zMlA{PTF|IN88US=> NIPib5ZUSU6JRWK=
NCI-H747 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XnNWlEPTB;Mz6wOVIxPiEQvF2= NVzXNnVDW0GQR1XS
CTB-1 NYfFWmNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT5XFZKSzVyPUOuNFU{PzZizszN MWDTRW5ITVJ?
RPMI-8226 NGX3O3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL0T2NKSzVyPUOuNVQ{PzhizszN M{LmfnNCVkeHUh?=
NCI-H2141 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HOUGlEPTB;Mz6xOlU3PiEQvF2= NXKxdZNDW0GQR1XS
IST-MES1 NWjHcXBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{iy[GlEPTB;Mz6xPFI4QSEQvF2= MXjTRW5ITVJ?
TE-5 NF74b3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHpTWM2OD1|LkKxN|QzKM7:TR?= NEX4cZpUSU6JRWK=
UACC-257 NETGeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqyTlZKSzVyPUOuOFM3PTlizszN MUPTRW5ITVJ?
SK-N-FI MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m5VGlEPTB;Mz60OVIzPyEQvF2= MkC2V2FPT0WU
MFH-ino MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTNwNE[1PFkh|ryP MV7TRW5ITVJ?
SF268 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDIZ2xiUUN3ME2zMlQ5OTd2IN88US=> MWXTRW5ITVJ?
TE-12 NVTFfIJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTNwNUG2PVkh|ryP NF;TTGNUSU6JRWK=
NB6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TyfWlEPTB;Mz61OVU3OyEQvF2= NGD5OmVUSU6JRWK=
DJM-1 M330TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\F[GlEPTB;Mz61PVg6QSEQvF2= NIfzPXZUSU6JRWK=
MZ1-PC NH3SfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTNwNkG2NlQh|ryP NF2xSm1USU6JRWK=
OCI-AML2 NUHLPWhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNwNkK2O|Eh|ryP M3T0fHNCVkeHUh?=
NCI-H1155 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG4dXJ3UUN3ME2zMlcxQTR5IN88US=> NEHIfYRUSU6JRWK=
RKO M4Hx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nUUWlEPTB;Mz63O|E5QSEQvF2= MXzTRW5ITVJ?
ECC4 NWXZOGppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTNwOUexPVUh|ryP NI\hO3BUSU6JRWK=
BB65-RCC NWTLbHNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\jTWM2OD1|Lkm3OVQ4KM7:TR?= MWjTRW5ITVJ?
EB-3 M4fYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr5W2d2UUN3ME2zMlk6PjN|IN88US=> NFXPd5pUSU6JRWK=
SHP-77 M1jLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnmTWM2OD12LkCwOVI1KM7:TR?= M1S0PXNCVkeHUh?=
NCI-H2196 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHq[|RtUUN3ME20MlA2PjJ3IN88US=> NWrTfItWW0GQR1XS
GI-ME-N NHXxV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvMe3FKSzVyPUSuNFY{QTlizszN NWPNfpB[W0GQR1XS
MN-60 NFq3TYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG5TJNnUUN3ME20MlExQDdizszN MoPmV2FPT0WU
NCI-H1694 NHe1dYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfzZWxMUUN3ME20MlE{PDB3IN88US=> NF;LeXlUSU6JRWK=
LU-65 NFL6Z4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PVSWlEPTB;ND6xOVM{OiEQvF2= NVfIW5RqW0GQR1XS
NCI-H1436 M3Lzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3JU2RlUUN3ME20MlE5OzN|IN88US=> MVHTRW5ITVJ?
KINGS-1 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV24e2lRUUN3ME20MlMyPDN{IN88US=> Mn36V2FPT0WU
GT3TKB NVfLfmhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLuTWM2OD12LkOzNlY5KM7:TR?= M4H5fHNCVkeHUh?=
Becker MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TySmlEPTB;ND6zO|MyOiEQvF2= NVzxU3dnW0GQR1XS
HCC1187 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjnTWM2OD12Lki5OlU4KM7:TR?= NH\IOY5USU6JRWK=
D-502MG NVT0c|RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjCTWM2OD13LkCwOFE3KM7:TR?= MUTTRW5ITVJ?
VA-ES-BJ MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PKXmlEPTB;NT6xN|c4QCEQvF2= M3zzdHNCVkeHUh?=
NB7 M2jDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7qe2ZoUUN3ME21MlE1OTF{IN88US=> NUP6cXVqW0GQR1XS
SW962 NXH0cYd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\ZXWlEPTB;NT6zPFgyPCEQvF2= M{jpd3NCVkeHUh?=
no-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7KfWVXUUN3ME21Mlc3OzR|IN88US=> NUnmbWN1W0GQR1XS
KNS-81-FD MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljSTWM2OD13LkmwOlk1KM7:TR?= NXnOclhTW0GQR1XS
COLO-684 M3;WXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS5PXk4UUN3ME21Mlk6PDl2IN88US=> NYnpe3ZyW0GQR1XS
D-263MG NEjNb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPJelJbUUN3ME22MlA5QDl3IN88US=> NVvhRWYyW0GQR1XS
EW-24 M4Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rC[mlEPTB;Nj6yPFUyKM7:TR?= MVHTRW5ITVJ?
TE-10 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTZwNEK2NlMh|ryP MmC2V2FPT0WU
EKVX MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjyTWM2OD14LkS2N|IyKM7:TR?= NX62NohmW0GQR1XS
NCI-H1648 M1XNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\aeGlEPTB;Nj62O|U2PyEQvF2= NFPOWWhUSU6JRWK=
LB771-HNC NVLncppOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqzTWM2OD14LkmyN|AyKM7:TR?= MoDVV2FPT0WU
SK-MEL-1 NHjoN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrmXopKSzVyPUiuNVMyPjZizszN M4O0d3NCVkeHUh?=
COLO-668 M2iwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fybmlEPTB;OD6yO|c5PiEQvF2= NIDEOYhUSU6JRWK=
EW-12 M1XVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq4[oRlUUN3ME24MlQxQDB|IN88US=> MnXHV2FPT0WU
A253 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXvOZpKSzVyPUiuPFQ3PjFizszN Mof1V2FPT0WU
NCI-H2126 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRThwOEmzNVkh|ryP NVjLfpVIW0GQR1XS
Calu-6 NXjJdXNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrkTWM2OD16Lkm5NFQzKM7:TR?= Mm\CV2FPT0WU
NCI-H23 M2HSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\lfm01UUN3ME25MlE4PzR4IN88US=> M33Y[HNCVkeHUh?=
WSU-NHL NI\4SZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HBVWlEPTB;OT63O|Q4QCEQvF2= MlTPV2FPT0WU
MMAC-SF NXvIW5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GwUGlEPTB;OT65O|kxPCEQvF2= NUHud4pZW0GQR1XS
SK-LMS-1 NFnuSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX3Vm1[UUN3ME2xNE4zQDN2IN88US=> M17IfXNCVkeHUh?=
GCIY NFfG[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFyLkW5NlQh|ryP Mn\KV2FPT0WU
TE-15 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrFTWM2OD1zMT62NFA1KM7:TR?= NH\ldWxUSU6JRWK=
EoL-1-cell Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjMTWM2OD1zMT63OlgzKM7:TR?= MkO0V2FPT0WU
NCI-H2081 NVHGb|ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MniyTWM2OD1zMT63O|g3KM7:TR?= NWrFbJR[W0GQR1XS
EW-3 M{XXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHVfZBKSzVyPUGyMlI1PjNizszN NGXkSW1USU6JRWK=
CAS-1 NF3UOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G1e2lEPTB;MUKuN|Y{OSEQvF2= NUXaXZpVW0GQR1XS
C2BBe1 MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF{Lk[xN|Eh|ryP MXrTRW5ITVJ?
D-247MG NEXJ[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF{Lke5OVIh|ryP M1G4e3NCVkeHUh?=
NCI-SNU-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi0V45KSzVyPUGyMlgxOTNizszN MYTTRW5ITVJ?
LS-1034 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:xXmlEPTB;MUSuN|k4PSEQvF2= MUfTRW5ITVJ?
EW-18 M1G2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X6dmlEPTB;MUSuOFQ5KM7:TR?= MXzTRW5ITVJ?
Raji NVLOVGJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3IUIFUUUN3ME2xOE42ODR7IN88US=> NWfSPIVqW0GQR1XS
D-283MED M{n6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P3VGlEPTB;MUSuOlI4OSEQvF2= NXHlWmY3W0GQR1XS
MZ2-MEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL2bVF6UUN3ME2xOE46Pjl4IN88US=> MVfTRW5ITVJ?
NCI-SNU-16 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofWTWM2OD1zNT60OlM{KM7:TR?= NYPzVHJGW0GQR1XS
P30-OHK MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\r[VRKSzVyPUG3Mlc5OzFizszN Mo\6V2FPT0WU
RXF393 NWHaZYM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPZTWM2OD1zOT6wNVg3KM7:TR?= NUfhV3ROW0GQR1XS
NCI-H1395 NIflSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;iTGJIUUN3ME2yNE43PzB|IN88US=> M2PtVHNCVkeHUh?=
U-698-M M{naSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJyLkewO|Uh|ryP M1TSUXNCVkeHUh?=
NCI-SNU-1 NEn4b|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJyLkeyNlMh|ryP MmLkV2FPT0WU
SW684 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDSeVJyUUN3ME2yNU4yPzF4IN88US=> MVPTRW5ITVJ?
NCI-H716 NXvTZ4VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fDZWlEPTB;MkGuN|E2PCEQvF2= NIPBXIpUSU6JRWK=
JVM-2 NF\5[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P1d2lEPTB;MkGuOFE{OyEQvF2= NXvQe2FxW0GQR1XS
NCI-H1581 MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\rTWM2OD1{Mj60NVQ5KM7:TR?= MlruV2FPT0WU
CA46 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq3bYN[UUN3ME2zNU43QTN4IN88US=> Moe1V2FPT0WU
SNB75 M4mzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN|Lk[1NFMh|ryP M4TITXNCVkeHUh?=
KNS-42 M{HGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN3Lkm2NlQh|ryP MXHTRW5ITVJ?
TUR MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vUbGlEPTB;M{[uNFUzOSEQvF2= NV:wU3N7W0GQR1XS
REH M4nKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nVZ2lEPTB;M{euPFIyOSEQvF2= MWnTRW5ITVJ?
EW-22 NWTkR5JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTR{LkK4PFUh|ryP NFv1[YxUSU6JRWK=
NCI-H446 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;iTWM2OD12Mj63PFU{KM7:TR?= NUfDOYxLW0GQR1XS
ES3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInOPHNKSzVyPUSzMlE{OzlizszN MkjuV2FPT0WU
EW-11 M3z5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjpTWM2OD12ND64NlE5KM7:TR?= MVzTRW5ITVJ?
RH-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITiVGdKSzVyPUS3MlU5OTJizszN NFTselFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID